Selank and Semax are both synthetic peptides developed in Russia and studied mostly within the Soviet and post-Soviet research tradition. Each is a short peptide analogue. Selank derives from tuftsin; Semax from a fragment of adrenocorticotropic hormone (ACTH). Both have drawn interest in neuroscience research for their reported effects on cognition and stress response. They share an origin and a loose label as "nootropic peptides," but their proposed mechanisms, receptor interactions, and research profiles differ in ways that matter.
Origins and Proposed Mechanisms
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide analogue of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro C-terminal sequence that increases metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Research describes it as interacting with the GABAergic system and modulating the expression of brain-derived neurotrophic factor (BDNF). Studies in the Russian literature report anxiolytic-like effects in animal models, with researchers noting an absence of the sedative profile typical of benzodiazepine-class compounds. Its proposed influence on enkephalin degradation has also been a subject of investigation.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of the ACTH(4–7) fragment, extended at its C-terminus with the same Pro-Gly-Pro sequence for stability. Research reports that it acts in part through modulation of BDNF and its TrkB receptor, and studies also describe effects on dopaminergic and serotonergic neurotransmission. Russian clinical research has investigated Semax in stroke recovery and cognitive function. It has been registered for medical use in Russia and Ukraine since the 1990s.
How They Differ
Both peptides show BDNF-related activity in reported findings, but their primary proposed targets diverge. Selank is more consistently tied in the literature to anxiolytic and stress-modulating activity through GABAergic pathways. Semax shows up more often in connection with neuroprotection, cognitive enhancement under stress, and neurotrophic signaling. Their sequences and structural origins are distinct, which points to different receptor binding profiles even where downstream effects overlap.
The bigger gap is in research footprint, not approval status. Both are registered prescription drugs in Russia. Semax is marketed as an intranasal solution indicated for conditions including ischemic stroke and cognitive impairment. Selank is marketed as an intranasal anxiolytic, reported by secondary sources to have been registered with the Russian Ministry of Health around 2009 for generalized anxiety disorder. Semax carries a substantially larger published clinical and preclinical literature than Selank. Outside Russia and Ukraine, neither holds regulatory approval. In jurisdictions including the United States and the European Union, both are sold strictly for research use only and are not approved for human consumption.
Comparison at a Glance
| Feature | Selank | Semax |
|---|---|---|
| Sequence origin | Tuftsin analogue | ACTH(4–7) analogue |
| Length | 7 amino acids | 7 amino acids |
| Primary reported activity | Anxiolytic, GABAergic modulation | Neuroprotective, neurotrophic signaling |
| BDNF involvement | Reported in studies | Reported in studies |
| Regulatory status (Russia) | Registered Rx anxiolytic (intranasal) | Registered Rx drug (intranasal) |
| Regulatory status (US/EU) | Not approved; research use | Not approved; research use |
| Research volume | Moderate; primarily Russian literature | Higher; includes clinical studies |
Research Context and Limitations
Published research on both compounds leans heavily toward Russian-language journals and Russian institutional studies, which independent researchers note can be harder to verify and replicate. Peer-reviewed English-language publications stay limited next to more widely studied peptides. The available animal model data and small human studies are often cited as preliminary, and independent replication outside the originating institutions is sparse.
Interest in Semax continues in the international literature. A 2025 study in the British Journal of Pharmacology reported that Semax acted on the μ-opioid receptor gene Oprm1 to promote functional recovery in a mouse model of spinal cord injury. Like most data on these peptides, that preclinical work has not been replicated in humans.
Anyone who runs into these compounds in a commercial setting outside Russia should note that products are marketed strictly as research chemicals. Quality, purity, and identity can vary a lot between suppliers. Independent third-party testing, such as the data tracked by platforms like Finnrick, Vial Audit, and PeptideBenchmark, is the main way researchers verify what is actually in a given vial.
Sources
- PubMed / NCBI — peptide neuropharmacology research
- NCBI PMC — Semax (ACTH(4–7)PGP) in a rat model of cerebral ischemia
- British Journal of Pharmacology — Semax and Oprm1 in spinal cord injury (2025)
- Finnrick — independent peptide vendor testing data
- Vial Audit — vendor reputation and test tracking
- PeptideBenchmark — independent peptide vendor reviews
- Bachem — reference peptide synthesis and characterization